Fotivda

Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC).[2] It is an oral VEGF receptor tyrosine kinase inhibitor.[2] The most common side effects include fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis.[2] Tivozanib was approved for medical use in the European Union in August 2017,[3&am... [wikipedia]